Stockscreener 앱 받기
57.00
0.41%
0.23
시간 외 거래:
57.00
전일 마감가:
$56.77
열려 있는:
$56.64
하루 거래량:
10.81M
Relative Volume:
0.93
시가총액:
$116.40B
수익:
$48.48B
순이익/손실:
$7.27B
주가수익비율:
16.00
EPS:
3.5626
순현금흐름:
$11.91B
1주 성능:
+1.50%
1개월 성능:
-1.54%
6개월 성능:
+22.19%
1년 성능:
+24.43%
1일 변동 폭
$56.14
$57.10
1주일 범위
$55.41
$57.10
52주 변동 폭
$42.52
$62.89
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, NVS, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.00 | 115.93B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,004.92 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.71 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.39 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Another pharma giant eyes Houston for $1B plant with hundreds of jobs possible - KHOU
Bristol Myers Squibb eyes Houston for $1B pharmaceutical plant - The Business Journals
Bristol Myers Squibb partners with Hengrui Pharma to develop and test drugs early in China. - Pluang
Biopharma Collaboration: Bristol Myers Squibb Partners with Heng - GuruFocus
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape - Oncodaily
Rx Rundown: Bristol Myers Squibb, Isomorphic Labs, Partner Therapeutics and more - Medical Marketing and Media
AustralianSuper Pty Ltd Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Strategic Advisers Fidelity Alternatives Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Sivia Capital Partners, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Benzinga
Tempus AI Stock (TEM) Opinions on Bristol Myers Squibb Partnership Expansion - Quiver Quantitative
Bristol-Myers Squibb Company stock (US0897961004): Dividend paid May 1 - AD HOC NEWS
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience - The Joplin Globe
AI aims to reshape Bristol Myers’ cancer and Alzheimer’s drug trials - Stock Titan
Bristol-Myers Squibb stock (US1101221083): China deal worth up to $15.2B - AD HOC NEWS
Bristol Myers Squibb Company $BMY Shares Sold by Bank Julius Baer & Co. Ltd Zurich - MarketBeat
MCDONALD PARTNERS LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration - Genetic Engineering and Biotechnology News
Bristol-Myers Shuts Down Lawsuit Over Celgene Investor Rights - Bloomberg Law News
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Cortisone Shots Market 2026 | Merck & Co, Pfizer, Bristol-Myers Squibb, Novartis, Pharmascience etc. - openPR.com
Bristol-Myers Squibb stock (US0897961004): $15.2B Hengrui Pharma drug partnership - AD HOC NEWS
Bernstein reiterates Bristol-Myers Squibb stock rating on China deal By Investing.com - Investing.com India
BMY Partners with Hengrui for $15.2 Billion Early-Stage Drug Dev - GuruFocus
Bernstein reiterates Bristol-Myers Squibb stock rating on China deal - Investing.com
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Jiangsu Hengrui Pharmaceutical Signs $15.2 Billion Drug Deal With Bristol Myers Squibb Ahead of Trump’s China Visit - Daily Pioneer
M Stanley: HENGRUI PHARMA (01276.HK) Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company (BMY.US) to Accelerate Globalization - AASTOCKS.com
Bristol Myers Squibb and Hengrui Pharma sign major licencing deal - FinanceAsia
NJ Court Not Sure Bristol-Myers Investor Pled Negligence - Law360
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology - BioPharma APAC
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up - WSJ
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal - BioWorld News
BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology
Bristol Myers Squibb (BMY) Valuation Check After Recent Share Weakness And Mixed 2024 Earnings - simplywall.st
Bristol Myers Squibb inks $15.2B drug deal with Hengrui - NJBIZ
Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B - MedCity News
Bristol-Myers Squibb stock (US1101221083): Stock dips despite strong Q1 2026 earnings - AD HOC NEWS
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal By Investing.com - Investing.com Nigeria
BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal - Investing.com UK
BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potentially $15.2 Billion - BioPharm International
Hengrui Pharma strikes $15.2 billion asset deal with BMS - The Pharma Letter
Hengrui Pharma and Bristol Myers Squibb Enter Strategic Collaboration to Advance Innovative Medicines - marketscreener.com
China's Hengrui, Bristol Myers Squibb sign collaboration, licensing deals - Reuters
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion - BioPharma Dive
BMS-Hengrui Pact Highlights China’s Rising Role in Drug Development - PharmTech.com
Hengrui Pharma and Bristol Myers Squibb to advance innovative medicines across oncology, hematology, immunology - BioSpectrum Asia
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal - BioSpace
China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS - Yicai Global
BMS, Hengrui strike $15.2B multi-asset pact - FirstWord Pharma
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.63%
자본화:
|
볼륨(24시간):